Mechanistically, NFKBIZ downregulation can suppress the expression of IL-6 (a hepatoprotective cytokine) and resulted in restricted inhibition of hepatitis; NFKBIZ can also regulate triglyceride metabolism to attenuate the progression of nonalcoholic fatty liver disease. This evidence concerns the gene NFKBIZ and metabolic dysfunction-associated steatotic liver disease.